Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 7.78% is 62% below its 5-year average of 20.45%, near the low end of its 5-year range (7.51%–29.94%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.05% below its 12-month average of 13.66%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 7.78%.
RETURN ON EQUITY (ROE)
7.78%
RETURN ON EQUITY (ROE) AVG TTM
13.66%
RETURN ON EQUITY (ROE) AVG 3Y
20.10%
RETURN ON EQUITY (ROE) AVG 5Y
20.45%
RETURN ON EQUITY (ROE) AVG 10Y
22.16%
RETURN ON EQUITY (ROE) AVG 15Y
-1.43%
RETURN ON EQUITY (ROE) AVG 20Y
-33.11%
CURRENT VS TTM AVG
-43.05%
CURRENT VS 3Y AVG
-61.30%
CURRENT VS 5Y AVG
-61.97%
CURRENT VS 10Y AVG
-64.90%
CURRENT VS 15Y AVG
+643.24%
CURRENT VS 20Y AVG
+123.49%
SECTOR MEDIAN · HEALTHCARE
-25.83%
median of 309 covered companies
CURRENT VS SECTOR MEDIAN
+130.11%
vs the sector median at left
Corcept Therapeutics Incorporated
Market Cap
$13.19B
Return on Equity (ROE)
7.78%
TTM Avg
13.66%
3Y Avg
20.10%
5Y Avg
20.45%
Market Cap
$12.95B
Return on Equity (ROE)
N/A
TTM Avg
35.81%
3Y Avg
39.37%
5Y Avg
-92.14%
Market Cap
$12.89B
Return on Equity (ROE)
3.51%
TTM Avg
5.40%
3Y Avg
5.85%
5Y Avg
7.17%
Market Cap
$12.52B
Return on Equity (ROE)
-17.13%
TTM Avg
-12.46%
3Y Avg
-8.76%
5Y Avg
-1.37%
Market Cap
$12.49B
Return on Equity (ROE)
10.49%
TTM Avg
6.83%
3Y Avg
5.29%
5Y Avg
3.21%
Market Cap
$14.16B
Return on Equity (ROE)
52.97%
TTM Avg
246.13%
3Y Avg
150.31%
5Y Avg
84.65%
Market Cap
$12.17B
Return on Equity (ROE)
14.35%
TTM Avg
4.54%
3Y Avg
-6.13%
5Y Avg
-2.52%
Market Cap
$12.00B
Return on Equity (ROE)
23.91%
TTM Avg
22.63%
3Y Avg
21.83%
5Y Avg
21.13%
Market Cap
$14.64B
Return on Equity (ROE)
-57.18%
TTM Avg
-651.33%
3Y Avg
-315.37%
5Y Avg
-198.08%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated (CORT) | $13.19B | 7.78% | 13.66% | 20.10% | 20.45% |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A | 35.81% | 39.37% | -92.14% |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 3.51% | 5.40% | 5.85% | 7.17% |
| Baxter International Inc. (BAX)vs › | $12.52B | -17.13% | -12.46% | -8.76% | -1.37% |
| Penumbra, Inc. (PEN)vs › | $12.49B | 10.49% | 6.83% | 5.29% | 3.21% |
| Ascendis Pharma A/S (ASND)vs › | $14.16B | 52.97% | 246.13% | 150.31% | 84.65% |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.17B | 14.35% | 4.54% | -6.13% | -2.52% |
| Encompass Health Corporation (EHC)vs › | $12.00B | 23.91% | 22.63% | 21.83% | 21.13% |
| Tempus AI, Inc. (TEM)vs › | $14.64B | -57.18% | -651.33% | -315.37% | -198.08% |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 46.68% | 29.72% | 22.87% | 17.28% |
ROE
7.8%
ROA
6.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 7.78% |
| 2026-03-31 | 7.51% |
| 2025-12-31 | 15.38% |
| 2025-09-30 | 16.74% |
| 2025-06-30 | 20.88% |
| 2025-03-31 | 19.48% |
| 2024-12-31 | 20.65% |
| 2024-09-30 | 22.12% |
| 2024-06-30 | 21.13% |
| 2024-03-31 | 21.54% |
| 2023-12-31 | 20.95% |
| 2023-09-30 | 19.79% |
| 2023-06-30 | 22.44% |
| 2023-03-31 | 17.84% |
| 2022-12-31 | 20.21% |
| 2022-09-30 | 24.69% |
| 2022-06-30 | 25.49% |
| 2022-03-31 | 27.43% |
| 2021-12-31 | 29.94% |
| 2021-09-30 | 19.71% |
| 2021-06-30 | 18.67% |
| 2021-03-31 | 19.46% |
| 2020-12-31 | 20.26% |
| 2020-09-30 | 22.34% |
| 2020-06-30 | 25.15% |
| 2020-03-31 | 25.88% |
| 2019-12-31 | 25.37% |
| 2019-09-30 | 25.96% |
| 2019-06-30 | 26.24% |
| 2019-03-31 | 26.67% |
| 2018-12-31 | 27.33% |
| 2018-09-30 | 58.46% |
| 2018-06-30 | 60.67% |
| 2018-03-31 | 66.07% |
| 2017-12-31 | 67.61% |
| 2017-09-30 | 41.01% |
| 2017-06-30 | 36.61% |
| 2017-03-31 | 25.31% |
| 2016-12-31 | 19.67% |
| 2016-09-30 | 14.41% |
| 2016-06-30 | 5.13% |
| 2016-03-31 | -7.92% |
| 2015-12-31 | -34.64% |
| 2015-09-30 | -83.56% |
| 2015-06-30 | -144.60% |
| 2015-03-31 | -210.77% |
| 2014-03-31 | -510.69% |
| 2013-12-31 | -218.92% |
| 2013-09-30 | -149.52% |
| 2013-06-30 | -107.50% |
| 2013-03-31 | -76.66% |
| 2012-12-31 | -61.59% |
| 2012-09-30 | -51.44% |
| 2012-06-30 | -106.71% |
| 2012-03-31 | -92.29% |
| 2011-12-31 | -92.95% |
| 2011-09-30 | -67.58% |
| 2011-06-30 | -61.76% |
| 2011-03-31 | -47.66% |
| 2010-12-31 | -122.22% |
| 2010-09-30 | -90.04% |
| 2010-06-30 | -65.00% |
| 2010-03-31 | -121.77% |
| 2009-12-31 | -91.28% |
| 2009-09-30 | -228.54% |
| 2009-06-30 | -163.79% |
| 2009-03-31 | -120.69% |
| 2008-12-31 | -118.66% |
| 2008-09-30 | -84.49% |
| 2008-06-30 | -61.54% |
| 2008-03-31 | -43.06% |
| 2007-12-31 | -78.55% |
| 2007-09-30 | -61.11% |
| 2007-06-30 | -123.89% |
| 2007-03-31 | -159.23% |
| 2006-12-31 | -391.10% |
| 2006-09-30 | -376.10% |
| 2006-06-30 | -193.31% |
| 2006-03-31 | -104.63% |
| 2005-12-31 | -75.56% |
| 2005-09-30 | -63.75% |
| 2005-06-30 | -51.94% |
| 2005-03-31 | -45.48% |
| 2004-12-31 | -33.81% |
| 2004-09-30 | -24.02% |
| 2004-06-30 | -18.74% |
| 2003-12-31 | -95.79% |
